Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Pricing
Rankings
For Publishers
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Pricing
Rankings
For Publishers
Log In
Start Free Trial
Sylvia K. Haas
Sign up to set email alerts
351
Publications
9,443
Citation Statements Received
5,103
Citation Statements Given
How they've been cited
13,314
427
8,908
108
How they cite others
7,680
242
4,815
46
Affiliations
Technical University of Munich
,
Klinikum rechts der Isar
Publications
Order By: Most citations
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson
1
,
Borris
2
,
Friedman
3
et al.
2008
N Engl J Med
Abstract
Show
1,411
24
1,071
3
Get article
Add to collection
Cite
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Kakkar
1
,
Brenner
2
,
Dahl
3
et al.
2008
The Lancet
1,042
14
810
1
Get article
Add to collection
Cite
Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients
Goldhaber
1
,
Leizorovicz
2
,
Kakkar
3
et al.
2011
N Engl J Med
555
4
429
3
Get article
Add to collection
Cite
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
Camm
1
,
Amarenco
2
,
Haas
3
et al.
2015
Eur Heart J
Abstract
Show
470
41
308
13
1
Get article
Add to collection
Cite
Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry
Kakkar
1
,
Mueller
,
Bassand
3
et al.
2013
PLoS ONE
Abstract
Show
457
19
308
7
Get article
Add to collection
Cite
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery
Mueck
1
,
Eriksson
2
,
Bauer
3
et al.
2008
Clinical Pharmacokinetics
Abstract
Show
245
24
294
2
Get article
Add to collection
Cite
Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement
Eriksson
1
,
Borris
2
,
Dahl
3
et al.
2006
Journal of Thrombosis and Haemostasis
Abstract
Show
305
8
292
0
Get article
Add to collection
Cite
A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement
Eriksson
1
,
Borris
2
,
Dahl
3
et al.
2006
Circulation
Abstract
Show
334
5
279
1
Get article
Add to collection
Cite
1
2
3
4
5